SAMRAT PHARMACHEM LTD.-$

Samrat Pharmachem Ltd has announced that its Board of Directors will convene on August 14, 2026, to consider and approve the Un-Audited Financial Results for the quarter ended June 30, 2026, prepared under Indian Accounting Standards (Ind-As). The meeting is scheduled to take place at the company's Corporate Office in Mumbai at 2:00 PM. Following the board's approval, the company will intimate the results to the stock exchanges and make them available on its website and in the press as per regulatory requirements.

Samrat Pharmachem Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended June 30, 2026. During this period, insiders are prohibited from trading in the company's shares, especially if they possess Unpublished Price Sensitive Information.

Samrat Pharmachem Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended June 30, 2026. During this period, no insider is permitted to trade in the company's shares, especially if in possession of Unpublished Price Sensitive Information.

Samrat Pharmachem Ltd. announced audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 30, 2026. Revenue from operations for the year stood at ₹28,972.12 lakhs. The company's 34th AGM will be held on September 23, 2026.

Samrat Pharmachem Ltd. announced the adoption of audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results at a meeting held on May 30, 2026. Revenue from operations stood at ₹28,972.12 lakhs for the year ended March 31, 2026, compared to ₹28,586.05 lakhs in the previous year. The company reported a loss for the year at ₹331.20 lakhs, against a profit of ₹711.22 lakhs last year. The 34th AGM is scheduled for September 23, 2026.

Samrat Pharmachem Ltd. has announced the closure of its trading window from April 1, 2026, till 48 hours after the declaration of the Audited Financial Results for the year ending March 31, 2026. This move is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's 'Code of Conduct for Prevention of Insider Trading'. The trading window closure applies to all designated persons, including their immediate relatives, who are prohibited from dealing in any transaction involving sale, purchase, or pledge of shares of the company during this period. The company emphasizes that no employee or insider should deal in the shares of the company while in possession of Unpublished Price Sensitive Information.

Samrat Pharmachem Ltd. has announced that its Board of Directors will meet on May 30, 2026, to consider and approve the Audited Standalone Financial Results for the financial year ended March 31, 2026. The meeting will be held at the Corporate Office of the Company in Mumbai. The company will intimate the exchanges about the Audited Financial Results upon the conclusion of the Board Meeting and will announce the same in the Press and on the company’s website as required under the Listing Agreement.

Samrat Pharmachem Ltd has reported its financial results for the quarter and nine months ended December 31, 2025. The total income for the quarter is INR 7,891.84 lakhs, while the total expenses stand at INR 7,966.68 lakhs, leading to a loss before tax of INR 74.84 lakhs. The company reported a loss for the year of INR 58.73 lakhs and a basic and diluted earnings per equity share of INR 1.90. The company's net worth as on December 31, 2025, is INR 2,585.19 lakhs.

Samrat Pharmachem Ltd. has reported its financial results for the quarter and nine months ended December 31, 2025. The company's revenue from operations stands at INR 6,342.61 lakhs for the quarter and INR 21,794.80 lakhs for the nine months period. The total income for the quarter is INR 6,382.71 lakhs and INR 21,908.84 lakhs for the nine months period. The net profit for the quarter is INR (45.95) lakhs and INR 278.48 lakhs for the nine months period. The earnings per equity share for the quarter is INR (1.49) and INR 9.01 for the nine months period.

Samrat Pharmachem Ltd. has announced that its Board of Directors will meet on February 13, 2026, to consider and approve the un-audited financial results for the quarter ended December 31, 2025. The meeting will take place at the company's corporate office in Mumbai.